Orthoclone OKT3 for graft failure after allogeneic bone marrow transplantation: a case report.
Orthoclone OKT3 has been used in the prophylaxis or treatment of acute graft-versus-host disease (GVHD). No previous report of Orthoclone OKT3 in the treatment of marrow allograft failure has been found. Here a case of chronic myelocytic leukemia is presented where the patient received unrelated bone marrow transplantation and developed late graft failure. After failing all other immunosuppressive agents, marrow allograft was successfully rescued by the use of Orthoclone OKT3.
Yen
C C
CC
Department of Medicine, Veterans General Hospital-Taipei, Taiwan, R.O.C.
Chen
P M
PM
Chiou
T J
TJ
Hsieh
R K
RK
D000208:Acute Disease; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D006086:Graft vs Host Disease / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3